Advanced acromegaly: successful disease control for more than 16 years using octreotide LA

Successful transfusion of platelets cryopreserved for more than 3 years.

To determine the duration of storage for cryopreserved platelets, 14 transfusions of random-donor, pooled platelets, stored in the vapor phase of liquid nitrogen for a mean period of 1157 days (range 1060-1240), were analyzed. Twelve of these transfusions were compared in a paired fashion with fresh, random-donor, pooled platelets given within a few days to the same thrombocytopenic recipients....

Octreotide as primary therapy for acromegaly.

The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation. These patients were part of a multicenter study that took place between 1989-1995. The study was divided into 3 phases beginning with a 1-mo...

Presurgical Octreotide: Treatment in Acromegaly

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 tLg octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2), In 18 group 2 patients, the dose was increased step...

Hemoclip retained for more than 2 years.

Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection.

A 27-year-old woman with a GH-secreting pituitary macroadenoma was treated with continuous s.c. infusion of octreotide prior to surgical resection. Subsequently, she was found to be 6 months pregnant. Fetal echographs were normal, the newborn had no malformation, and postnatal development was normal.